Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KAT-007
- Development stage
- Preclinical
- Lead developer
- New G Lab Pharma
- Modality
- Small Molecules
01
Overview
KAT-007 is a small molecule anticancer therapeutic being developed by NewG Lab Pharma as part of its KoDiscovery Anticancer Therapeutics (KAT) pipeline. The drug is specifically designed to target the Warburg Effect, also known as aerobic glycolysis, which is a metabolic hallmark of cancer cells where they preferentially ferment glucose into lactate even in the presence of oxygen. By inhibiting this metabolic pathway, KAT-007 aims to disrupt the energy supply and biosynthetic precursors required for rapid tumor growth. The primary target indication for KAT-007 is prostate cancer. As of the latest pipeline information, the drug is in the early stages of development with its specific clinical phase and location yet to be determined.
Beyond the preview
Go deeper on KAT-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KAT-007.